Tools   Select Another Resource Report Type

http://www.orion.fi/en/

A globally operating Finnish developer, manufacturer and marketer of human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. They are continuously developing new drugs and treatment methods. Pharmaceutical RD focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler pulmonary drugs.

Proper citation: Orion (RRID:SCR_003911) Copy   

•   Source: SciCrunch Registry

http://www.gene.com/

A biotechnology corporation that uses human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions.

Proper citation: Genentech (RRID:SCR_003997) Copy   

•   Source: SciCrunch Registry

http://www.eisai.com/

A global pharmaceutical company.

Proper citation: Eisai (RRID:SCR_003936) Copy   

•   Source: SciCrunch Registry

http://www.eortc.org/clinical-trials

A database that contains information about EORTC (European Organisation for Research and Treatment of Cancer) clinical trials but also clinical trials from other organizations, in which EORTC has been/is participating. The protocol database may be browsed by EORTC Research Group, tumor site, treatment, or drug.

Proper citation: EORTC Clinical Trials (RRID:SCR_004011) Copy   

•   Source: SciCrunch Registry

http://www.proteomics.com/

Commercial company delivering content for personalized medicine in the areas of Biomarker Services, Biomarker Assays, Isobaric and Isotopic Reagents and Proprietary Biomarkers. A global leader in applied proteomics, they use high sensitivity proprietary technologies to detect biomarkers (differentially expressed proteins in diseases) and to develop rapid assays for testing. The biomarkers discovered in body fluids or tissues are validated, developed and commercialized as diagnostic, prognostic or therapeutic products through strategic alliances and out-licensing.

Proper citation: Proteome Sciences (RRID:SCR_004106) Copy   

•   Source: SciCrunch Registry

http://www.thebindingsite.com/

Company provides specialist diagnostic products to clinicians and laboratory professionals worldwide. Specialist protein company committed to research, development, manufacture and distribution of immunodiagnostic assays for global laboratory market. Specialized in antibody specificity technology, Binding Site gives clinicians and laboratory staff tools to significantly improve diagnosis and management of those patients with specific cancers and immune disorders. Binding Site manufactures wide range of products for plasma protein analysis including Freelite, Hevylite and SPAplus.

Proper citation: Binding Site (RRID:SCR_004051) Copy   

•   Source: SciCrunch Registry

http://www.eortc.org/

An independent pan-European clinical research organization to improve the standards of cancer care through the multidisciplinary multinational efforts of basic scientists and clinicians. The efforts include the testing of more effective therapeutic strategies based on drugs, surgery and/or radiotherapy that are already in use. They also contribute to the development of new drugs and other approaches in partnership with the pharmaceutical industry which is accomplished mainly by conducting large, multicenter, prospective, randomized, phase III clinical trials. The EORTC Network comprises over 300 hospitals and cancer centers in over 30 countries which include some 2,500 collaborators from all disciplines involved in cancer treatment and research. The EORTC Headquarters staff handle some 6,000 new patients enrolled each year in cancer clinical trials, approximately 30 protocols that are permanently open to patient entry, over 50,000 patients who are in follow-up, and a database of more than 180,000 patients. Intergroup collaboration is also promoted to face current challenges of clinical trials aiming at targeted therapies in order to recruit a large number of patients within a reasonable period of time.

Proper citation: EORTC (RRID:SCR_004070) Copy   

•   Source: SciCrunch Registry

http://norccentral.org

Portal to research centers and core facilities specifically support obesity research and better understand the relationship between health and nutrition.

Proper citation: Nutrition and Obesity Research Centers (RRID:SCR_004131) Copy   

•   Source: SciCrunch Registry

http://www.dukecancerinstitute.org/

One of 40 centers in the country designated by the National Cancer Institute (NCI) as a comprehensive cancer center, it combines cutting-edge research with compassionate care. Its vision is to accelerate research advances related to cancer and improve Duke''s ability to translate these discoveries into the most advanced cancer care to patients by uniting hundreds of cancer physicians, researchers, educators, and staff across the medical center, medical school, and health system under a shared administrative structure.

Proper citation: Duke Cancer Institute (RRID:SCR_004338) Copy   

•   Source: SciCrunch Registry

http://discovery.hsci.harvard.edu/

An online database of curated cancer stem cell (CSC) experiments coupled to the Galaxy analytical framework. Driven by a need to improve our understanding of molecular processes that are common and unique across cancer stem cells (CSCs), the SCDE allows users to consistently describe, share and compare CSC data at the gene and pathway level. The initial focus has been on carefully curating tissue and cancer stem cell-related experiments from blood, intestine and brain to create a high quality resource containing 53 public studies and 1098 assays. The experimental information is captured and stored in the multi-omics Investigation/Study/Assay (ISA-Tab) format and can be queried in the data repository. A linked Galaxy framework provides a comprehensive, flexible environment populated with novel tools for gene list comparisons against molecular signatures in GeneSigDB and MSigDB, curated experiments in the SCDE and pathways in WikiPathways. Investigation/Study/Assay (ISA) infrastructure is the first general-purpose format and freely available desktop software suite targeted to experimentalists, curators and developers and that: * assists in the reporting and local management of experimental metadata (i.e. sample characteristics, technology and measurement types, sample-to-data relationships) from studies employing one or a combination of technologies; * empowers users to uptake community-defined minimum information checklists and ontologies, where required; * formats studies for submission to a growing number of international public repositories endorsing the tools, currently ENA (genomics), PRIDE (proteomics) and ArrayExpress (transcriptomics). Galaxy allows you to do analyses you cannot do anywhere else without the need to install or download anything. You can analyze multiple alignments, compare genomic annotations, profile metagenomic samples and much much more. Best of all, Galaxy''''s history system provides a complete analyses record that can be shared. Every history is an analysis workflow, which can be used to reproduce the entire experiment. The code for this Galaxy instance is available for download from BitBucket.

Proper citation: Stem Cell Discovery Engine (RRID:SCR_004453) Copy   

•   Source: SciCrunch Registry

http://www.fnih.org/

A public charity whose mission is to support the NIH in its mission to improve health, by forming and facilitating public-private partnerships for biomedical research and training. Its vision is Building Partnerships for Discovery and Innovation to Improve Health. The FNIH draws together the world''s foremost researchers and resources, pressing the frontier to advance critical discoveries. They are recognized as the number-one medical research charity in the countryleveraging support, and convening high level partnerships, for the greatest impact on the most urgent medical challenges we face today. Grants are awarded as part of a public-private partnership with the National Heart, Lung, and Blood Institute (NHLBI) on behalf of The Heart Truth in support of women''s heart health education and research. Funding for the Community Action Program is provided by the FNIH through donations from individuals and corporations including The Heart Truth partners Belk Department Stores, Diet Coke, and Swarovski. Successful biomedical research relies upon the knowledge, training and dedication of those who conduct it. Bringing multiple disciplines to bear on health challenges requires innovation and collaboration on the part of scientists. Foundation for NIH partnerships operate in a variety of ways and formats to recruit, train, empower and retain their next generation of researchers. From lectures and multi-week courses, to scholarships and awards through fellowships and residential training programs, their programs respond to the needs of scientists at every level and stage in their careers.

Proper citation: Foundation for the National Institutes of Health (RRID:SCR_004493) Copy   

•   Source: SciCrunch Registry

http://dgidb.genome.wustl.edu/

A database of drug-gene relationships that provides drug-gene interactions and potential druggability data given list of genes. There are about 15 data sources that are being aggregated by DGIdb, with update date and these data sources are listed on this page: http://dgidb.genome.wustl.edu/sources, THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: DGIdb (RRID:SCR_006608) Copy   

•   Source: SciCrunch Registry

http://p53.fr

The UMD TP53 Mutation Database is a novel web site exclusively dedicated to mutant TP53. The following datasets, analytical tools and software are available. * The TP53 UMD mutation database in human cancer (2012 release). This novel release (35,000 mutations, 3,600 publications) has been highly curated using an original and novel statistical procedure (See Edlung et al. PNAS 2012). * TP53MUTLOAD (MUTant Loss Of Activity Database), a novel database dedicated to detailed analysis of the properties of each TP53 mutant, ranging from transactivation to cell growth properties, change of conformation, localization or various gains of functions. The database contains more than 110,000 different entries. * TP53 Mut assessor, a novel stand-alone software available for both Windows and Mac users. Check your favorite TP53 mutants and get an instant identity card. Very useful to analyze any newly discovered TP53 mutants, as the software checks for every possible TP53 mutation. * MUT-TP53 2.0, an accurate and powerful tool that automatically manages p53 mutations and generate tables ready for publication, decreasing the risk of typing errors. MUT-TP53 2.0 also provides specific information for each TP53 mutation, allowing the user to assess the quality of the data. Up to 500 TP53 mutations can be managed simultaneously.

Proper citation: UMD p53 Mutation Database (RRID:SCR_006720) Copy   

•   Source: SciCrunch Registry

http://www.proteinatlas.org/

Open access resource for human proteins. Used to search for specific genes or proteins or explore different resources, each focusing on particular aspect of the genome-wide analysis of the human proteins: Tissue, Brain, Single Cell, Subcellular, Cancer, Blood, Cell line, Structure and Interaction. Swedish-based program to map all human proteins in cells, tissues, and organs using integration of various omics technologies, including antibody-based imaging, mass spectrometry-based proteomics, transcriptomics, and systems biology. All the data in the knowledge resource is open access to allow scientists both in academia and industry to freely access the data for exploration of the human proteome.

Proper citation: The Human Protein Atlas (RRID:SCR_006710) Copy   

•   Source: SciCrunch Registry

http://purl.bioontology.org/ontology/CANCO

A vocabulary that is able to describe and semantically interconnect the different paradigms of the cancer chemoprevention domain.

Proper citation: Cancer Chemoprevention Ontology (RRID:SCR_006966) Copy   

•   Source: SciCrunch Registry

https://sites.google.com/site/drivermutationidentification/

Computational tool developed to help identify cancer-associated ''driver'' mutations from ''passenger'' ones in a cancer genome.

Proper citation: DMI (RRID:SCR_008599) Copy   

•   Source: SciCrunch Registry

http://www.kreftregisteret.no/en/

Comprises 3 registries of cancer patients in Norway: the Incidence Registry, the Clinical Registry and Cancer Statistics. The Incidence Registry contains the basic data items collected from clinicians and pathologists, as well as from administrative discharge and mortality sources. It is updated continuously with information on both new cases, as well as cases diagnosed in previous years. All medical doctors in the country are instructed by law to notify new cancer cases. Clinical Registries: Registration of treatment and follow-up of Norwegian cancer patients. Clinical registries comprehensive registration schemes dedicated to specific cancers have been established to include detailed information on diagnostic measures, therapy, and follow-up. Cancer Statistics: Database of cancer statistics. The Cancer Registry of Norway is maintained by the Institute of Population-based Cancer Research and established in 1951. It is one of the oldest national cancer registries in the world. This, combined with the unique personal identification number used in Norway, makes the Cancer Registry''s data suitable, also internationally; by establishing new knowledge through research and spreading information on cancer.

Proper citation: Cancer Registry of Norway (RRID:SCR_008879) Copy   

•   Source: SciCrunch Registry

http://cancer.ucsf.edu/

The UCSF Helen Diller Family Comprehensive Cancer Center combines basic science, clinical research, epidemiology/cancer control, and patient care throughout the University of California, San Francisco. UCSF''s long tradition of excellence in cancer research includes, notably, the Nobel Prize-winning work of J. Michael Bishop and Harold Varmus, who discovered cancer-causing oncogenes. Their work opened new doors for exploring genetic mistakes that cause cancer, and formed the basis for some of the most important cancer research happening today. * Basic Scientific Research: From understanding normal cellular processes and replication to discovering the underlying molecular and genetic causes of cancer when these processes go awry, UCSF researchers are committed to moving scientific insights beyond model systems and pursuing their relevance for clinical oncology and cancer prevention. * Clinical Research: Clinical scientists explore how greater understanding of fundamental biological events can be transformed into clinically relevant tools. New forms of cancer treatment, as well as innovations in diagnosis and prognosis, undergo rigorous evaluation for safety and efficacytranslating into improved patient outcomes and hope for the future. * Patient Care: The Helen Diller Family Comprehensive Cancer Center provides superlative cancer patient care at four San Francisco medical centers: UCSF Medical Center at Mount Zion; UCSF Medical Center at Parnassus; San Francisco General Hospital; and the San Francisco Veterans Affairs Medical Center. * Population Science: Cancer population sciences at UCSF includes a broad range of research on the causes of new cancers and the sickness and death due to the disease in order to develop ways to improve the prevention and early detection of cancer as well as the quality of life following diagnosis and treatment for all of Northern California''s diverse populations.

Proper citation: UCSF Helen Diller Family Comprehensive Cancer Center (RRID:SCR_008857) Copy   

•   Source: SciCrunch Registry

http://www.cancerimagingarchive.net/

Archive of medical images of cancer accessible for public download. All images are stored in DICOM file format and organized as Collections, typically patients related by common disease (e.g. lung cancer), image modality (MRI, CT, etc) or research focus. Neuroimaging data sets include clinical outcomes, pathology, and genomics in addition to DICOM images. Submitting Data Proposals are welcomed.

Proper citation: Cancer Imaging Archive (TCIA) (RRID:SCR_008927) Copy   

•   Source: SciCrunch Registry

http://www.terryfox.org/

The Terry Fox Foundation is responsible for supporting close to $20 million in discovery based research each year in Canada - all monies raised outside Canada must be distributed to (a) an institute approved by the Foundation and its advisors or (b) remitted to Canada. The Terry Fox Research Institute (TFRI) is a recipient of TFF funding for translational research. TFRI is an exciting new initiative whose goal is to translate rapidly today''s best science into better cancer treatment and diagnosis for all Canadians. The Institute will bring scientists and clinicians together across the country into a functionally integrated, geographically dispersed Institute with nodes in several provinces. Terry Fox was diagnosed with osteogenic sarcoma (bone cancer) in his right leg in 1977 and had his leg amputated 15 cm (six inches) above the knee. While in hospital, Terry was so overcome by the suffering of other cancer patients that he decided to run across Canada to raise money for cancer research. He called his journey the Marathon of Hope. Terry''s Marathon of Hope took place in 1980 with the simple objective of informing Canadians of the importance of finding a cure for cancer. With fierce determination, he ran an average of 42 kilometres (26 miles) every day for 143 days. Terry was forced to end his run on September 1, 1980 when the cancer spread to his lungs. By February 1, 1981, Terry''s dream of raising $1 for every Canadian was realized - the Terry Fox Marathon of Hope fund totaled $24.17 million. Terry died in June 1981. On May 26, 1988, The Terry Fox Run became a Trust, independent from the Canadian Cancer Society, and received tax-exempt charitable registration as a public foundation. In addition to our signature and long-standing National Terry Fox Run Day in September of each year, The Terry Fox Foundation is proud to include in its events portfolio The National School Run Day. The Foundation recognizes the duality of its mandate. Not only does it raise money for research, but it also continues to share the story of Terry Fox. The Terry Fox Foundation strives to maintain the heroic effort and integrity that Terry embodied. It is a grassroots organization that does not allow the Terry Fox name or likeness to be commercialized or conjoined with other worthy causes. To date, over $600 million has been raised worldwide for cancer research in Terry''s name.

Proper citation: Terry Fox Foundation (RRID:SCR_005873) Copy   

•   Source: SciCrunch Registry